Chevy Chase Trust Holdings LLC Has $339.39 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Chevy Chase Trust Holdings LLC reduced its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 6.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,921,241 shares of the company’s stock after selling 125,314 shares during the quarter. Johnson & Johnson accounts for approximately 1.4% of Chevy Chase Trust Holdings LLC’s holdings, making the stock its 8th biggest holding. Chevy Chase Trust Holdings LLC owned approximately 0.07% of Johnson & Johnson worth $339,387,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Nordwand Advisors LLC purchased a new position in Johnson & Johnson during the fourth quarter valued at approximately $785,273,000. Savant Capital LLC lifted its stake in shares of Johnson & Johnson by 8,568.8% during the fourth quarter. Savant Capital LLC now owns 3,630,127 shares of the company’s stock worth $29,637,000 after buying an additional 3,588,251 shares during the period. Edmp Inc. lifted its stake in shares of Johnson & Johnson by 17,222.9% during the fourth quarter. Edmp Inc. now owns 3,223,265 shares of the company’s stock worth $18,247,000 after buying an additional 3,204,658 shares during the period. Vanguard Group Inc. lifted its stake in shares of Johnson & Johnson by 1.2% during the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after buying an additional 2,815,655 shares during the period. Finally, GQG Partners LLC lifted its stake in shares of Johnson & Johnson by 64.4% during the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after buying an additional 2,547,378 shares during the period. 67.94% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.3 %

JNJ stock opened at $158.91 on Monday. The stock has a market capitalization of $412.96 billion, a P/E ratio of 33.24, a P/E/G ratio of 2.71 and a beta of 0.53. The firm has a 50-day simple moving average of $159.70 and a 200-day simple moving average of $166.20. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $183.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its earnings results on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. The business had revenue of $24.75 billion during the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The company’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.67 earnings per share. Equities analysts forecast that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be given a dividend of $1.19 per share. The ex-dividend date of this dividend is Monday, May 22nd. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 dividend on an annualized basis and a yield of 3.00%. Johnson & Johnson’s payout ratio is presently 94.56%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on JNJ. Raymond James lowered their price objective on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research note on Wednesday, April 19th. Guggenheim started coverage on shares of Johnson & Johnson in a research report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 target price for the company. Piper Sandler decreased their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Finally, Atlantic Securities decreased their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research report on Wednesday, April 19th. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $173.00.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.20% of the stock is currently owned by company insiders.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.